nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—DRD5—eyelid—skin cancer	0.0839	0.315	CbGeAlD
Zuclopenthixol—HRH1—nose—skin cancer	0.0278	0.104	CbGeAlD
Zuclopenthixol—DRD1—nerve—skin cancer	0.0171	0.0641	CbGeAlD
Zuclopenthixol—HTR2A—hindlimb—skin cancer	0.0109	0.0411	CbGeAlD
Zuclopenthixol—DRD2—nerve—skin cancer	0.0101	0.0379	CbGeAlD
Zuclopenthixol—HTR2A—appendage—skin cancer	0.00939	0.0352	CbGeAlD
Zuclopenthixol—HTR2A—nerve—skin cancer	0.00666	0.025	CbGeAlD
Zuclopenthixol—DRD5—lymphoid tissue—skin cancer	0.00658	0.0247	CbGeAlD
Zuclopenthixol—DRD5—female reproductive system—skin cancer	0.00635	0.0238	CbGeAlD
Zuclopenthixol—HTR2A—endothelium—skin cancer	0.00567	0.0213	CbGeAlD
Zuclopenthixol—HTR6—head—skin cancer	0.00545	0.0204	CbGeAlD
Zuclopenthixol—DRD5—head—skin cancer	0.0053	0.0199	CbGeAlD
Zuclopenthixol—HTR2A—blood vessel—skin cancer	0.00523	0.0196	CbGeAlD
Zuclopenthixol—HRH1—nipple—skin cancer	0.00453	0.017	CbGeAlD
Zuclopenthixol—ADRA2A—nipple—skin cancer	0.00445	0.0167	CbGeAlD
Zuclopenthixol—DRD1—head—skin cancer	0.00405	0.0152	CbGeAlD
Zuclopenthixol—ADRA1A—epithelium—skin cancer	0.00394	0.0148	CbGeAlD
Zuclopenthixol—HTR2A—neck—skin cancer	0.00374	0.014	CbGeAlD
Zuclopenthixol—HRH1—connective tissue—skin cancer	0.00321	0.012	CbGeAlD
Zuclopenthixol—ADRA2A—connective tissue—skin cancer	0.00315	0.0118	CbGeAlD
Zuclopenthixol—HRH1—epithelium—skin cancer	0.00305	0.0114	CbGeAlD
Zuclopenthixol—ADRA1A—lymphoid tissue—skin cancer	0.00303	0.0114	CbGeAlD
Zuclopenthixol—HTR2A—connective tissue—skin cancer	0.00268	0.0101	CbGeAlD
Zuclopenthixol—HRH1—mammalian vulva—skin cancer	0.00264	0.00992	CbGeAlD
Zuclopenthixol—ADRA2A—mammalian vulva—skin cancer	0.0026	0.00974	CbGeAlD
Zuclopenthixol—HTR2A—epithelium—skin cancer	0.00254	0.00955	CbGeAlD
Zuclopenthixol—ADRA1A—head—skin cancer	0.00244	0.00917	CbGeAlD
Zuclopenthixol—DRD2—head—skin cancer	0.00239	0.00899	CbGeAlD
Zuclopenthixol—HRH1—female reproductive system—skin cancer	0.00226	0.0085	CbGeAlD
Zuclopenthixol—ADRA2A—female reproductive system—skin cancer	0.00222	0.00834	CbGeAlD
Zuclopenthixol—HRH1—head—skin cancer	0.00189	0.0071	CbGeAlD
Zuclopenthixol—HTR2A—female reproductive system—skin cancer	0.00189	0.0071	CbGeAlD
Zuclopenthixol—Weight decreased—Temozolomide—skin cancer	0.00188	0.00256	CcSEcCtD
Zuclopenthixol—Anorexia—Imiquimod—skin cancer	0.00188	0.00256	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Temozolomide—skin cancer	0.00188	0.00256	CcSEcCtD
Zuclopenthixol—ADRA2A—head—skin cancer	0.00186	0.00697	CbGeAlD
Zuclopenthixol—Body temperature increased—Vemurafenib—skin cancer	0.00183	0.00249	CcSEcCtD
Zuclopenthixol—Pancytopenia—Fluorouracil—skin cancer	0.00182	0.00248	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Imiquimod—skin cancer	0.0018	0.00245	CcSEcCtD
Zuclopenthixol—Insomnia—Imiquimod—skin cancer	0.00178	0.00243	CcSEcCtD
Zuclopenthixol—Paraesthesia—Imiquimod—skin cancer	0.00177	0.00242	CcSEcCtD
Zuclopenthixol—Dyspnoea—Imiquimod—skin cancer	0.00176	0.0024	CcSEcCtD
Zuclopenthixol—Somnolence—Imiquimod—skin cancer	0.00175	0.00239	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Temozolomide—skin cancer	0.00175	0.00239	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Fluorouracil—skin cancer	0.00175	0.00238	CcSEcCtD
Zuclopenthixol—Dyspepsia—Imiquimod—skin cancer	0.00174	0.00237	CcSEcCtD
Zuclopenthixol—CYP2D6—female reproductive system—skin cancer	0.00172	0.00646	CbGeAlD
Zuclopenthixol—Erythema—Bleomycin—skin cancer	0.00172	0.00234	CcSEcCtD
Zuclopenthixol—Decreased appetite—Imiquimod—skin cancer	0.00172	0.00234	CcSEcCtD
Zuclopenthixol—Hot flush—Docetaxel—skin cancer	0.00171	0.00233	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Vemurafenib—skin cancer	0.0017	0.00232	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Imiquimod—skin cancer	0.0017	0.00232	CcSEcCtD
Zuclopenthixol—Fatigue—Imiquimod—skin cancer	0.0017	0.00232	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Docetaxel—skin cancer	0.0017	0.00231	CcSEcCtD
Zuclopenthixol—Pain—Imiquimod—skin cancer	0.00169	0.0023	CcSEcCtD
Zuclopenthixol—Asthenia—Vemurafenib—skin cancer	0.00166	0.00226	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Temozolomide—skin cancer	0.00164	0.00224	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Temozolomide—skin cancer	0.00164	0.00223	CcSEcCtD
Zuclopenthixol—Pruritus—Vemurafenib—skin cancer	0.00164	0.00223	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Temozolomide—skin cancer	0.00164	0.00223	CcSEcCtD
Zuclopenthixol—Urethral disorder—Temozolomide—skin cancer	0.00163	0.00222	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Imiquimod—skin cancer	0.00163	0.00222	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Imiquimod—skin cancer	0.00161	0.0022	CcSEcCtD
Zuclopenthixol—Visual impairment—Temozolomide—skin cancer	0.0016	0.00219	CcSEcCtD
Zuclopenthixol—Erythema—Dactinomycin—skin cancer	0.0016	0.00218	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Fluorouracil—skin cancer	0.00159	0.00217	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Bleomycin—skin cancer	0.00159	0.00217	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vemurafenib—skin cancer	0.00158	0.00216	CcSEcCtD
Zuclopenthixol—HTR2A—head—skin cancer	0.00158	0.00593	CbGeAlD
Zuclopenthixol—Migraine—Docetaxel—skin cancer	0.00157	0.00215	CcSEcCtD
Zuclopenthixol—Body temperature increased—Imiquimod—skin cancer	0.00156	0.00213	CcSEcCtD
Zuclopenthixol—Abdominal pain—Imiquimod—skin cancer	0.00156	0.00213	CcSEcCtD
Zuclopenthixol—Eye disorder—Temozolomide—skin cancer	0.00156	0.00212	CcSEcCtD
Zuclopenthixol—Tinnitus—Temozolomide—skin cancer	0.00155	0.00212	CcSEcCtD
Zuclopenthixol—Malaise—Bleomycin—skin cancer	0.00155	0.00211	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Temozolomide—skin cancer	0.00154	0.00211	CcSEcCtD
Zuclopenthixol—Leukopenia—Bleomycin—skin cancer	0.00154	0.0021	CcSEcCtD
Zuclopenthixol—Dizziness—Vemurafenib—skin cancer	0.00153	0.00209	CcSEcCtD
Zuclopenthixol—Angiopathy—Temozolomide—skin cancer	0.00151	0.00206	CcSEcCtD
Zuclopenthixol—Ataxia—Docetaxel—skin cancer	0.0015	0.00205	CcSEcCtD
Zuclopenthixol—Immune system disorder—Temozolomide—skin cancer	0.0015	0.00205	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Dactinomycin—skin cancer	0.00149	0.00203	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Docetaxel—skin cancer	0.00148	0.00201	CcSEcCtD
Zuclopenthixol—Vomiting—Vemurafenib—skin cancer	0.00147	0.00201	CcSEcCtD
Zuclopenthixol—Myalgia—Bleomycin—skin cancer	0.00146	0.00199	CcSEcCtD
Zuclopenthixol—Rash—Vemurafenib—skin cancer	0.00146	0.00199	CcSEcCtD
Zuclopenthixol—Mental disorder—Temozolomide—skin cancer	0.00146	0.00199	CcSEcCtD
Zuclopenthixol—Dermatitis—Vemurafenib—skin cancer	0.00146	0.00199	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Imiquimod—skin cancer	0.00145	0.00198	CcSEcCtD
Zuclopenthixol—Headache—Vemurafenib—skin cancer	0.00145	0.00198	CcSEcCtD
Zuclopenthixol—Erythema—Temozolomide—skin cancer	0.00145	0.00197	CcSEcCtD
Zuclopenthixol—Malnutrition—Temozolomide—skin cancer	0.00145	0.00197	CcSEcCtD
Zuclopenthixol—Breast disorder—Docetaxel—skin cancer	0.00145	0.00197	CcSEcCtD
Zuclopenthixol—Discomfort—Bleomycin—skin cancer	0.00144	0.00197	CcSEcCtD
Zuclopenthixol—Malaise—Dactinomycin—skin cancer	0.00144	0.00197	CcSEcCtD
Zuclopenthixol—CYP2D6—head—skin cancer	0.00144	0.0054	CbGeAlD
Zuclopenthixol—Leukopenia—Dactinomycin—skin cancer	0.00143	0.00195	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Docetaxel—skin cancer	0.00143	0.00195	CcSEcCtD
Zuclopenthixol—Asthenia—Imiquimod—skin cancer	0.00142	0.00193	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00141	0.00192	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Bleomycin—skin cancer	0.0014	0.00191	CcSEcCtD
Zuclopenthixol—Pruritus—Imiquimod—skin cancer	0.0014	0.0019	CcSEcCtD
Zuclopenthixol—Nausea—Vemurafenib—skin cancer	0.00137	0.00187	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Bleomycin—skin cancer	0.00137	0.00187	CcSEcCtD
Zuclopenthixol—Arrhythmia—Fluorouracil—skin cancer	0.00137	0.00187	CcSEcCtD
Zuclopenthixol—Vision blurred—Temozolomide—skin cancer	0.00137	0.00186	CcSEcCtD
Zuclopenthixol—Myalgia—Dactinomycin—skin cancer	0.00136	0.00186	CcSEcCtD
Zuclopenthixol—Tremor—Temozolomide—skin cancer	0.00136	0.00185	CcSEcCtD
Zuclopenthixol—Diarrhoea—Imiquimod—skin cancer	0.00135	0.00184	CcSEcCtD
Zuclopenthixol—Discomfort—Dactinomycin—skin cancer	0.00135	0.00184	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Temozolomide—skin cancer	0.00134	0.00183	CcSEcCtD
Zuclopenthixol—Anorexia—Bleomycin—skin cancer	0.00134	0.00182	CcSEcCtD
Zuclopenthixol—Erythema—Fluorouracil—skin cancer	0.00133	0.00182	CcSEcCtD
Zuclopenthixol—Agitation—Temozolomide—skin cancer	0.00133	0.00181	CcSEcCtD
Zuclopenthixol—HRH1—lymph node—skin cancer	0.00132	0.00497	CbGeAlD
Zuclopenthixol—Pancytopenia—Docetaxel—skin cancer	0.00131	0.00179	CcSEcCtD
Zuclopenthixol—Hypotension—Bleomycin—skin cancer	0.00131	0.00179	CcSEcCtD
Zuclopenthixol—Malaise—Temozolomide—skin cancer	0.00131	0.00178	CcSEcCtD
Zuclopenthixol—Dizziness—Imiquimod—skin cancer	0.0013	0.00178	CcSEcCtD
Zuclopenthixol—Vertigo—Temozolomide—skin cancer	0.0013	0.00177	CcSEcCtD
Zuclopenthixol—ADRA2A—lymph node—skin cancer	0.0013	0.00488	CbGeAlD
Zuclopenthixol—Leukopenia—Temozolomide—skin cancer	0.0013	0.00177	CcSEcCtD
Zuclopenthixol—Neutropenia—Docetaxel—skin cancer	0.00129	0.00176	CcSEcCtD
Zuclopenthixol—Palpitations—Temozolomide—skin cancer	0.00128	0.00175	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Dactinomycin—skin cancer	0.00128	0.00174	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00128	0.00174	CcSEcCtD
Zuclopenthixol—Paraesthesia—Bleomycin—skin cancer	0.00126	0.00172	CcSEcCtD
Zuclopenthixol—Weight increased—Docetaxel—skin cancer	0.00126	0.00172	CcSEcCtD
Zuclopenthixol—Vision blurred—Fluorouracil—skin cancer	0.00126	0.00171	CcSEcCtD
Zuclopenthixol—Convulsion—Temozolomide—skin cancer	0.00126	0.00171	CcSEcCtD
Zuclopenthixol—Vomiting—Imiquimod—skin cancer	0.00125	0.00171	CcSEcCtD
Zuclopenthixol—Weight decreased—Docetaxel—skin cancer	0.00125	0.00171	CcSEcCtD
Zuclopenthixol—Hypertension—Temozolomide—skin cancer	0.00125	0.00171	CcSEcCtD
Zuclopenthixol—Dyspnoea—Bleomycin—skin cancer	0.00125	0.0017	CcSEcCtD
Zuclopenthixol—Anorexia—Dactinomycin—skin cancer	0.00125	0.0017	CcSEcCtD
Zuclopenthixol—Rash—Imiquimod—skin cancer	0.00124	0.0017	CcSEcCtD
Zuclopenthixol—Dermatitis—Imiquimod—skin cancer	0.00124	0.00169	CcSEcCtD
Zuclopenthixol—Headache—Imiquimod—skin cancer	0.00124	0.00168	CcSEcCtD
Zuclopenthixol—Myalgia—Temozolomide—skin cancer	0.00123	0.00168	CcSEcCtD
Zuclopenthixol—Anxiety—Temozolomide—skin cancer	0.00123	0.00168	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00122	0.00167	CcSEcCtD
Zuclopenthixol—Discomfort—Temozolomide—skin cancer	0.00122	0.00166	CcSEcCtD
Zuclopenthixol—Decreased appetite—Bleomycin—skin cancer	0.00122	0.00166	CcSEcCtD
Zuclopenthixol—Dry mouth—Temozolomide—skin cancer	0.00121	0.00164	CcSEcCtD
Zuclopenthixol—Jaundice—Docetaxel—skin cancer	0.0012	0.00164	CcSEcCtD
Zuclopenthixol—Pain—Bleomycin—skin cancer	0.0012	0.00163	CcSEcCtD
Zuclopenthixol—Leukopenia—Fluorouracil—skin cancer	0.00119	0.00163	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00119	0.00162	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Temozolomide—skin cancer	0.00118	0.00161	CcSEcCtD
Zuclopenthixol—Nausea—Imiquimod—skin cancer	0.00117	0.0016	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Docetaxel—skin cancer	0.00117	0.00159	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Temozolomide—skin cancer	0.00116	0.00158	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Temozolomide—skin cancer	0.00116	0.00158	CcSEcCtD
Zuclopenthixol—Convulsion—Fluorouracil—skin cancer	0.00116	0.00158	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Bleomycin—skin cancer	0.00116	0.00157	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Docetaxel—skin cancer	0.00115	0.00157	CcSEcCtD
Zuclopenthixol—Skin disorder—Temozolomide—skin cancer	0.00115	0.00157	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Temozolomide—skin cancer	0.00114	0.00156	CcSEcCtD
Zuclopenthixol—Myalgia—Fluorouracil—skin cancer	0.00114	0.00155	CcSEcCtD
Zuclopenthixol—Decreased appetite—Dactinomycin—skin cancer	0.00114	0.00155	CcSEcCtD
Zuclopenthixol—Fatigue—Dactinomycin—skin cancer	0.00113	0.00154	CcSEcCtD
Zuclopenthixol—Anorexia—Temozolomide—skin cancer	0.00113	0.00154	CcSEcCtD
Zuclopenthixol—Discomfort—Fluorouracil—skin cancer	0.00112	0.00153	CcSEcCtD
Zuclopenthixol—Pain—Dactinomycin—skin cancer	0.00112	0.00152	CcSEcCtD
Zuclopenthixol—Body temperature increased—Bleomycin—skin cancer	0.00111	0.00151	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Docetaxel—skin cancer	0.00109	0.00149	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Docetaxel—skin cancer	0.00109	0.00149	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Fluorouracil—skin cancer	0.00109	0.00149	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Docetaxel—skin cancer	0.00109	0.00148	CcSEcCtD
Zuclopenthixol—Urethral disorder—Docetaxel—skin cancer	0.00108	0.00148	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Dactinomycin—skin cancer	0.00108	0.00147	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00108	0.00147	CcSEcCtD
Zuclopenthixol—Insomnia—Temozolomide—skin cancer	0.00107	0.00146	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Dactinomycin—skin cancer	0.00107	0.00146	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Fluorouracil—skin cancer	0.00107	0.00146	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Fluorouracil—skin cancer	0.00107	0.00145	CcSEcCtD
Zuclopenthixol—Visual impairment—Docetaxel—skin cancer	0.00107	0.00145	CcSEcCtD
Zuclopenthixol—Tachycardia—Fluorouracil—skin cancer	0.00106	0.00145	CcSEcCtD
Zuclopenthixol—Paraesthesia—Temozolomide—skin cancer	0.00106	0.00145	CcSEcCtD
Zuclopenthixol—Dyspnoea—Temozolomide—skin cancer	0.00105	0.00144	CcSEcCtD
Zuclopenthixol—Somnolence—Temozolomide—skin cancer	0.00105	0.00143	CcSEcCtD
Zuclopenthixol—Dyspepsia—Temozolomide—skin cancer	0.00104	0.00142	CcSEcCtD
Zuclopenthixol—Anorexia—Fluorouracil—skin cancer	0.00104	0.00142	CcSEcCtD
Zuclopenthixol—Eye disorder—Docetaxel—skin cancer	0.00103	0.00141	CcSEcCtD
Zuclopenthixol—Abdominal pain—Dactinomycin—skin cancer	0.00103	0.00141	CcSEcCtD
Zuclopenthixol—Body temperature increased—Dactinomycin—skin cancer	0.00103	0.00141	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Bleomycin—skin cancer	0.00103	0.00141	CcSEcCtD
Zuclopenthixol—Decreased appetite—Temozolomide—skin cancer	0.00103	0.0014	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Docetaxel—skin cancer	0.00103	0.0014	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Temozolomide—skin cancer	0.00102	0.00139	CcSEcCtD
Zuclopenthixol—Fatigue—Temozolomide—skin cancer	0.00102	0.00139	CcSEcCtD
Zuclopenthixol—Hypotension—Fluorouracil—skin cancer	0.00102	0.00139	CcSEcCtD
Zuclopenthixol—Constipation—Temozolomide—skin cancer	0.00101	0.00138	CcSEcCtD
Zuclopenthixol—Pain—Temozolomide—skin cancer	0.00101	0.00138	CcSEcCtD
Zuclopenthixol—Asthenia—Bleomycin—skin cancer	0.00101	0.00137	CcSEcCtD
Zuclopenthixol—Angiopathy—Docetaxel—skin cancer	0.001	0.00137	CcSEcCtD
Zuclopenthixol—Immune system disorder—Docetaxel—skin cancer	0.001	0.00136	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000993	0.00135	CcSEcCtD
Zuclopenthixol—Pruritus—Bleomycin—skin cancer	0.000992	0.00135	CcSEcCtD
Zuclopenthixol—Arrhythmia—Docetaxel—skin cancer	0.000989	0.00135	CcSEcCtD
Zuclopenthixol—Insomnia—Fluorouracil—skin cancer	0.000985	0.00134	CcSEcCtD
Zuclopenthixol—Paraesthesia—Fluorouracil—skin cancer	0.000978	0.00133	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Temozolomide—skin cancer	0.000974	0.00133	CcSEcCtD
Zuclopenthixol—Dyspnoea—Fluorouracil—skin cancer	0.000971	0.00132	CcSEcCtD
Zuclopenthixol—Mental disorder—Docetaxel—skin cancer	0.00097	0.00132	CcSEcCtD
Zuclopenthixol—Somnolence—Fluorouracil—skin cancer	0.000968	0.00132	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Temozolomide—skin cancer	0.000967	0.00132	CcSEcCtD
Zuclopenthixol—Erythema—Docetaxel—skin cancer	0.000963	0.00131	CcSEcCtD
Zuclopenthixol—Malnutrition—Docetaxel—skin cancer	0.000963	0.00131	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Dactinomycin—skin cancer	0.000963	0.00131	CcSEcCtD
Zuclopenthixol—Dyspepsia—Fluorouracil—skin cancer	0.000959	0.00131	CcSEcCtD
Zuclopenthixol—Decreased appetite—Fluorouracil—skin cancer	0.000947	0.00129	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000941	0.00128	CcSEcCtD
Zuclopenthixol—Asthenia—Dactinomycin—skin cancer	0.000938	0.00128	CcSEcCtD
Zuclopenthixol—Abdominal pain—Temozolomide—skin cancer	0.000935	0.00127	CcSEcCtD
Zuclopenthixol—Body temperature increased—Temozolomide—skin cancer	0.000935	0.00127	CcSEcCtD
Zuclopenthixol—Pain—Fluorouracil—skin cancer	0.000932	0.00127	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Fluorouracil—skin cancer	0.000898	0.00122	CcSEcCtD
Zuclopenthixol—Diarrhoea—Dactinomycin—skin cancer	0.000894	0.00122	CcSEcCtD
Zuclopenthixol—Vomiting—Bleomycin—skin cancer	0.000891	0.00121	CcSEcCtD
Zuclopenthixol—Rash—Bleomycin—skin cancer	0.000884	0.0012	CcSEcCtD
Zuclopenthixol—Dermatitis—Bleomycin—skin cancer	0.000883	0.0012	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Temozolomide—skin cancer	0.000871	0.00119	CcSEcCtD
Zuclopenthixol—Syncope—Docetaxel—skin cancer	0.000864	0.00118	CcSEcCtD
Zuclopenthixol—Leukopenia—Docetaxel—skin cancer	0.000862	0.00118	CcSEcCtD
Zuclopenthixol—Body temperature increased—Fluorouracil—skin cancer	0.000861	0.00117	CcSEcCtD
Zuclopenthixol—Palpitations—Docetaxel—skin cancer	0.000851	0.00116	CcSEcCtD
Zuclopenthixol—Asthenia—Temozolomide—skin cancer	0.000848	0.00116	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Docetaxel—skin cancer	0.000847	0.00115	CcSEcCtD
Zuclopenthixol—Pruritus—Temozolomide—skin cancer	0.000837	0.00114	CcSEcCtD
Zuclopenthixol—Convulsion—Docetaxel—skin cancer	0.000835	0.00114	CcSEcCtD
Zuclopenthixol—Nausea—Bleomycin—skin cancer	0.000833	0.00113	CcSEcCtD
Zuclopenthixol—Hypertension—Docetaxel—skin cancer	0.000832	0.00113	CcSEcCtD
Zuclopenthixol—Vomiting—Dactinomycin—skin cancer	0.000831	0.00113	CcSEcCtD
Zuclopenthixol—Rash—Dactinomycin—skin cancer	0.000824	0.00112	CcSEcCtD
Zuclopenthixol—Myalgia—Docetaxel—skin cancer	0.00082	0.00112	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000815	0.00111	CcSEcCtD
Zuclopenthixol—Diarrhoea—Temozolomide—skin cancer	0.000809	0.0011	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Fluorouracil—skin cancer	0.000803	0.00109	CcSEcCtD
Zuclopenthixol—Dry mouth—Docetaxel—skin cancer	0.000802	0.00109	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Docetaxel—skin cancer	0.000786	0.00107	CcSEcCtD
Zuclopenthixol—Dizziness—Temozolomide—skin cancer	0.000782	0.00107	CcSEcCtD
Zuclopenthixol—Nausea—Dactinomycin—skin cancer	0.000776	0.00106	CcSEcCtD
Zuclopenthixol—Shock—Docetaxel—skin cancer	0.000774	0.00105	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Docetaxel—skin cancer	0.000771	0.00105	CcSEcCtD
Zuclopenthixol—Pruritus—Fluorouracil—skin cancer	0.000771	0.00105	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Docetaxel—skin cancer	0.00077	0.00105	CcSEcCtD
Zuclopenthixol—Tachycardia—Docetaxel—skin cancer	0.000767	0.00105	CcSEcCtD
Zuclopenthixol—Skin disorder—Docetaxel—skin cancer	0.000764	0.00104	CcSEcCtD
Zuclopenthixol—Vomiting—Temozolomide—skin cancer	0.000752	0.00102	CcSEcCtD
Zuclopenthixol—Anorexia—Docetaxel—skin cancer	0.000749	0.00102	CcSEcCtD
Zuclopenthixol—Rash—Temozolomide—skin cancer	0.000745	0.00102	CcSEcCtD
Zuclopenthixol—Diarrhoea—Fluorouracil—skin cancer	0.000745	0.00102	CcSEcCtD
Zuclopenthixol—Dermatitis—Temozolomide—skin cancer	0.000745	0.00102	CcSEcCtD
Zuclopenthixol—Headache—Temozolomide—skin cancer	0.000741	0.00101	CcSEcCtD
Zuclopenthixol—Hypotension—Docetaxel—skin cancer	0.000735	0.001	CcSEcCtD
Zuclopenthixol—Dizziness—Fluorouracil—skin cancer	0.00072	0.000982	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000716	0.000977	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—skin cancer	0.000711	0.000969	CcSEcCtD
Zuclopenthixol—Paraesthesia—Docetaxel—skin cancer	0.000706	0.000963	CcSEcCtD
Zuclopenthixol—Nausea—Temozolomide—skin cancer	0.000702	0.000957	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—skin cancer	0.000701	0.000956	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—skin cancer	0.000699	0.000953	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—skin cancer	0.000693	0.000944	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—skin cancer	0.000692	0.000944	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—skin cancer	0.000687	0.000936	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—skin cancer	0.000686	0.000936	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—skin cancer	0.000684	0.000932	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—skin cancer	0.000682	0.00093	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—skin cancer	0.000679	0.000925	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—skin cancer	0.000678	0.000924	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—skin cancer	0.000672	0.000917	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—skin cancer	0.000672	0.000917	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Docetaxel—skin cancer	0.000648	0.000883	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—skin cancer	0.000647	0.000882	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—skin cancer	0.000643	0.000877	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—skin cancer	0.000622	0.000847	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—skin cancer	0.000622	0.000847	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—skin cancer	0.000579	0.00079	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—skin cancer	0.000564	0.000769	CcSEcCtD
Zuclopenthixol—Pruritus—Docetaxel—skin cancer	0.000556	0.000758	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—skin cancer	0.000538	0.000733	CcSEcCtD
Zuclopenthixol—Dizziness—Docetaxel—skin cancer	0.00052	0.000709	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—skin cancer	0.0005	0.000682	CcSEcCtD
Zuclopenthixol—Rash—Docetaxel—skin cancer	0.000496	0.000676	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—skin cancer	0.000495	0.000675	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—skin cancer	0.000493	0.000672	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—skin cancer	0.000467	0.000637	CcSEcCtD
